American Shared Hospital Services — FY 2014 Form 10-K
Reporting period: Fiscal year ended December 31, 2014. This is an annual filing, not a standalone fourth-quarter report; the filing text does not provide clear Q4-only financial results. The company provides Gamma Knife radiosurgery and image-guided radiation therapy equipment and services, primarily to hospitals.
Financial performance and position
| Metric | FY 2014 | FY 2013 |
|---|---|---|
| Revenue | $15.417 million | $17.584 million |
| Gross margin | $5.279 million; 34.2% of revenue | $6.944 million; 39.5% |
| Operating income (loss) | $(50,000); approximately (0.3)% margin | $1.120 million; approximately 6.4% |
| Net income (loss) | $(562,000) consolidated; $(952,000) attributable to ASHS | $(113,000) consolidated; $(312,000) attributable to ASHS |
| Diluted loss per share attributable to ASHS | $(0.19) | $(0.07) |
| Cash from operating activities | $6.773 million | $8.076 million |
| Cash and cash equivalents at year-end | $1.059 million | $1.909 million |
| Working capital | $(2.004) million | $(4.079) million |
Gamma Knife revenue was $14.521 million, down 10.0%; procedures fell 17.6% to 2,046, while average revenue per procedure rose 9.2% to $7,097. IGRT revenue was $896,000, down 38.5%. Gamma Knife represented 94% of revenue and IGRT 6%. No customer accounted for more than 10% of revenue, although six customers together generated more than half.
Costs of revenue were $10.138 million (65.8% of revenue), including $6.171 million of depreciation and amortization. Selling and administrative expense was $3.630 million; interest expense was $1.699 million. Cash from operations exceeded $5.212 million of property and equipment purchases, but cash declined by $850,000 during the year.
At December 31, 2014, long-term debt and capital leases totaled $26.884 million, excluding the $8.780 million drawn on the bank line of credit. The $9.000 million certificate of deposit securing that line was used to repay it on January 2, 2015. The company reported $9.000 million of certificate-of-deposit liquidity at year-end and negative working capital. Total assets were $67.528 million and shareholders’ equity was $26.154 million.
Material changes and unusual items
- Revenue declined 12.3%, reflecting the Turkey subsidiary sale, lower procedures at certain existing sites, and lower IGRT volume. Sale of EWRS Turkey contributed $999,000 to the total revenue decline.
- EWRS Turkey was sold in June 2014 for approximately $6.0 million. Proceeds paid related debt; $768,000 was reported as cash proceeds to the company. ASHS recorded a $572,000 loss on sale, including release of $779,000 of accumulated currency translation adjustments. The sale was not classified as discontinued operations.
- The 2014 loss attributable to ASHS worsened by $640,000 from 2013, primarily due to the Turkey-sale loss; operating results also weakened as gross margin declined.
- In December 2014, the company recorded $700,000 of equipment received in a nonmonetary transaction and recognized deferred revenue.
- The company issued 750,000 shares to directors in private placements for approximately $1.8 million and received $1.0 million in director promissory notes bearing 15% interest, with warrants to purchase 200,000 shares at $2.20. Proceeds, together with cash, funded Mevion deposits.
Outlook, risks, and contingencies
- CMS established a comprehensive APC reimbursement rate of approximately $9,768 for one-session Gamma Knife and LINAC cranial radiosurgery effective January 1, 2015. Management estimated an increase of $4,168 per Medicare Gamma Knife treatment compared with the prior average delivery and ancillary reimbursement; the rate is subject to future policy changes.
- The company had commitments of approximately $45.434 million for three proton beam systems, Gamma Knife equipment, and cobalt reloads, against $7.784 million of deposits. Approximately $27 million was not expected to become due until 2016. Financing for the first proton project included a $9 million lease-financing commitment pending definitive documents; permanent financing for the proton units had not been finalized.
- The first MEVION S250 system was delivered to the Orlando Health site in November 2014; the company anticipated first patient treatment in early 2016. The first system in operation, at Barnes-Jewish Hospital, began treating patients in December 2013. ASHS carried its approximately 0.77% Mevion interest at $2.709 million despite estimating an approximately $2.4 million unrealized impairment; management judged the impairment temporary. A write-down could materially affect earnings and financial condition.
- Key risks include high debt and capital needs, customer and procedure concentration, uncertain hospital contract renewals, competition and technology obsolescence, Medicare reimbursement changes, and the limited market and low trading volume for the company’s shares. Revenue-sharing arrangements have no minimum-volume guarantees.
- The company disclosed a prior profitability-covenant failure on its line of credit; the bank waived it in August 2014, and the borrowing was repaid after year-end. Management said it met covenants under other lender notes. Contractual obligations totaled $87.058 million, including equipment commitments.
- Management reported effective disclosure controls and internal control over financial reporting. The independent auditor issued an unqualified opinion on the consolidated financial statements; it did not audit or opine on internal control effectiveness.
Investor verification priorities
- Track post-2014 Gamma Knife procedures, per-procedure revenue, and realized reimbursement following the 2015 CMS APC change.
- Verify the repayment and replacement funding of the line of credit, debt covenant compliance, and ability to meet near-term debt and lease payments.
- Confirm financing, construction milestones, delivery obligations, and expected treatment start dates for the three proton systems; assess the resulting cash requirements.
- Review the assumptions supporting the Mevion investment’s carrying value and the potential for impairment or further dilution.
- Assess the sustainability of customer volumes and contract renewals, especially given that six customers generated more than half of 2014 revenue.
- Reconcile the Turkey sale proceeds, reported loss, associated debt relief, and any earn-out; the filing says the earn-out could not be estimated.